Overview

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Status:
Enrolling by invitation

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

To investigate the safety and tolerability of GLS-010 in subjects with advanced solid tumors (mainly gastric cancer, esophageal cancer). To investigate the preliminary relationship between the expression of the ligand of PD-1 (PD-L1) and efficacy.

Phase:

Phase 1

Details

Lead Sponsor:

Guangzhou Gloria Biosciences Co., Ltd.

Treatments:

Antibodies
Antibodies, Monoclonal
Immunoglobulins